IFN beta-1a for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Darazam NCT04521400		RCT	high-dose IFN beta-1a	IFN beta-1a	COVID 19 hospitalized	some concern	83/85	inconclusive
SOLIDARITY (interferon) NCT04315948		RCT	IFN beta-1a	control	COVID 19 hospitalized	some concern	2063/2064	inconclusive	inconclusive 16 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
COVID-19 severe or critically meta-analysis
Kalil (ACTT-3) NCT04492475		RCT	IFN beta-1a	placebo	COVID-19 severe or critically	some concern	487/482	inconclusive	inconclusive 1 % decrease in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 severe or critically meta-analysis